Nicotine

(NIK-oh-TEEN)

Trade Name(s):
Habitrol
  • Transdermal system
  • 17.5 mg
  • Transdermal system
  • 35 mg
  • Transdermal system
  • 52.5 mg

    Nicoderm
  • Transdermal system
  • 36 mg
  • Transdermal system
  • 78 mg
  • Transdermal system
  • 114 mg

    Nicorette
  • Chewing gum
  • 2 mg/square

    Nicorette DS
  • Chewing gum
  • 4 mg/square

    Nicotrol
  • Transdermal system
  • 8.3 mg
  • Transdermal system
  • 16.6 mg
  • Transdermal system
  • 24.9 mg

    Nicotrol NS
  • Spray pump
  • 0.5 mg nicotine/actuation

    Nicotrol Inhaler
  • Inhaler
  • 4 mg delivered (10 mg/cartridge)

    ProStep
  • Transdermal system
  • 15 mg
  • Transdermal system
  • 30 mg

    Nicorette Plus
    Indicates Canadian trade names.

    Class:   Smoking deterrent

      Action:
    Reduces nicotine withdrawal symptoms by providing nicotine levels lower than those associated with smoking.

      Indications:
    Aid to smoking cessation. Part of comprehensive behavioral smoking-cessation program.

      Contraindications:
    Nonsmokers; during immediate post-MI period; life-threatening arrhythmias; severe or worsening angina pectoris; active temporomandibular joint disease (nicotine
    Polacrilex [gum]).

      Route/Dosage:
    Advise patient to stop smoking completely when beginning to use smoking cessation therapy.

    Nicotine Gum

    Adults:
    PO If patient smokes < 25 cigarettes/day, chew 2 mg gum (max 24 pieces/day) for up to 12 wk. If patient smokes 25 cigarettes/day, chew 4 mg gum (max 24 pieces/day) for up to 12 wk.

    Nicotine Inhaler

    Adults:
    Inhaler 6 to 16 cartridges/day for up to 6 mo.

    Nicotine Transdermal Patches

    Adults:
    Topical (
    Habitrol) If patient smokes 10 cigarettes/day, start with 21 mg/day for first 4 wk, then decrease dose to 14 mg/day for next 2 wk, then decrease dose to 7 mg/day for last 2 wk. If patient smokes < 10 cigarettes/day, start with 14 mg/day for 6 wk then decrease dose to 7 mg/day for last 2 wk. (
    Nicoderm) If patient smokes 10 cigarettes/day, start with 21 mg/day for first 6 wk then decrease dose to 14 mg/day for next 2 wk, then decrease dose to 7 mg/day for last 2 wk. If patient smokes < 10 cigarettes/day, start with 14 mg/day for 6 wk then decrease dose to 7 mg/day for last 2 wk. (
    Nicotrol ) Use 15 mg/16 hr for 6 wk.

    Nicotine Nasal Spray

    Adults:
    Spray (Each actuation delivers 50 mcL spray containing 0.5 mg nicotine.) 8 to 40 doses/day for 3 to 6 months.

      Interactions:

    Acetaminophen, caffeine, imipramine, oxazepam, pentazocine, propanolol, theophylline: Smoking tends to increase metabolism and may lower blood levels of these drugs or others. Smoking cessation, with or without nicotine medication, may reverse these effects.

    Food: Effective absorption of nicotine gum depends on mildly alkaline saliva. Coffee, cola, and other drinks or food may reduce salivary pH and should probably be avoided 15 min before and during chewing of gum.

      Lab Test Interferences:
    None well documented.

      Adverse Reactions:

    CV:
    Edema; flushing; hypertension; palpitations; tachyarrhythmias; tachycardia; MI; CHF; cardiac arrest; cerebrovascular accident.
    CNS:
    Insomnia; dizziness; lightheadedness; irritability; headache; impaired concentration; confusion; convulsions; depression; paresthesia; abnormal dreams.
    DERM:
    Erythema; rash; itching; urticaria.
    EENT:
    Buccal cavity irritation; mouth or throat soreness or dryness. With gum chewing: traumatic injury to oral mucosa or teeth; jaw ache; changes in taste perception.
    GI:
    GI distress; belching; indigestion; nausea; vomiting; excess salivation; hiccoughs; anorexia; constipation; diarrhea.
    HEPA:
    Alterations of LFTs.
    RESP:
    Increased cough; pharyngitis; sinusitis; difficulty breathing; hoarseness; sneezing.
    OTHER:
    Pain; myalgia; arthralgia; dysmenorrhea.

      Precautions:

    Pregnancy: Category C (nicotine polacrilex gum); Category D (inhaler, spray, transdermal nicotine).

    Lactation: Excreted in breast milk.

    Children: Safety and efficacy not established.

    Elderly or debilitated patients: May be more susceptible to adverse effects.

    Abuse/Dependence: Transference of nicotine dependence from smoking to deterrent product exists. If patient continues to smoke while on nicotine therapy, patient may experience severe effects because of higher nicotine levels.

    Cardiovascular effects: Patients with coronary heart disease, serious cardiac arrhythmias, systemic hypertension, or vasospastic disease need to be carefully evaluated and monitored closely because of cardiac effects.

    Dental problems: Might be exacerbated by chewing nicotine gum.

    Endocrine effects: Use with caution in patients with hyperthyroidism, pheochromocytoma, or insulin-dependent diabetes because of action of nicotine on adrenal medulla.

    GI effects: May delay healing in patients with peptic ulcer disease.

    Hepatic impairment: May reduce nicotine clearance.


    Patient Care Considerations

      Administration/Storage:

    Transdermal system

    Nicotine chewing gum

    Nasal spray

      Assessment/Interventions:


    OVERDOSAGE: SIGNS & SYMPTOMS
    Nausea, salivation, abdominal pain, vomiting, diarrhea, cold sweat, headache, dizziness, disturbed hearing and vision, mental confusion, marked weakness, faintness, prostration, hypotension, difficult breathing, rapid, weak, irregular pulse, respiratory collapse

      Patient/Family Education:

    Nasal spray


    AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons